Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients

Investigating the Clinical Value of Tumor Antigen-Specific T Cells and Immune Cell Balance in Peripheral Blood of Non-Small Cell Lung Cancer Patients for Prognostic Evaluation.

Participants needed: 200
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Zhao JunUpdated: Nov 21, 2025Locations: 1
Eligibility criteria

Age 18 to 80 years. [+4]

Received any neoadjuvant therapy prior to surgery. [+4]

Status: Recruiting

Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer

Participants needed: 150
Trial details
Biological sex: AllType: ObservationalSponsor: Zhao JunUpdated: Jul 2, 2025Locations: 1Duration: 2 Years
Eligibility criteria

Patient underwent a ct examination [+4]

Patient has no ct examination results [+9]

Status: Recruiting

Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients

This study aims to investigate the impact of immunotherapy on the immune status of tumor microenvironment and peripheral blood of chest cancer patients. To do so, the investigators plan to collect tumor tissue and peripheral blood samples before and after immunotherapy, and use single-cell RNA sequencing, Multiplex immunohistochemistry, and flow cytometry. The investigators will analyze changes in the proportion of cancer cell-specific T-cell subpopulations related to treatment response before and after therapy, and seek biological markers that can predict the efficacy of immunotherapy.

Participants needed: 50
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Zhao JunUpdated: Jan 24, 2025Locations: 1
Eligibility criteria

Patients with a pathological diagnosis of lung cancer or esophageal cancer who h... [+5]

Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepat... [+7]